Joshua Linscott, MD, PhD

Cancer Focus:
Bladder Cancer, Kidney (Renal Cell) Cancer, Prostate Cancer

Dr. Linscott received his PhD in Pharmacology from Weill Cornell Medical College, New York City. He received his MD degree at Tufts University School of Medicine, Boston, Massachusetts. Dr. Linscott completed a Urology Residency at Maine Medical Center, Portland, followed by Urologic Oncology fellowship at Moffitt Cancer Center, Tampa.

Dr. Linscott specializes in the treatment of patients with early and locally advanced bladder cancer, kidney cancer, and prostate cancer. He is a translational researcher focused on urothelial carcinoma, with a particular interest in the discovery and development of urinary cell-free DNA biomarkers. Dr. Linscott’s research goals include defining patterns of urinary cell-free DNA methylation as predictors of treatment response and disease progression, as well as studying the tumor immune microenvironment in BCG-treated patients using spatial transcriptomics.

Clinical Trial 22623
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in localized bladder cancer
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab (); FK228 (Romidepsin); MEDI4736 (Durvalumab); Romidepsin ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Zhao D, Khatri VM, Nakashima JY, Chadha J, Chatwal M, Zhang J, Ionescu F, Linscott JA, Li R, Poch M, Sexton W, Yu A, Spiess PE, Zemp L, Gilbert SM, Manley B, Yin V, Jain R, Torres-Roca J, Johnstone P, Yamoah K, Grass GD. Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy. J Urol. 2026 Mar.215(3):305-315. Pubmedid: 41231842.
• White RE, Linscott JA, Pelletier C, Santos E, James E, Cole A, Platteter E, Howard JM, Ryan ST, Hayn MT, Sammon JD. Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes. Urol Oncol. 2026 Jul.44(7):316-322. Pubmedid: 42106216.
• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2026 Jan.12(1):38-40. Pubmedid: 40716995.
• Guske C, Immen N, Conant D, Laborde J, Linscott J, Hayes M, Jazayeri SB, Fazili A, Siegel E, Dessureault S, Sanchez J, Stefanou A, Manley B, Felder S. Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer. Cancer Control. 2025 Jan.32:10732748251316598. Pubmedid: 39848249. Pmcid: PMC11758541.
• Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb.87(2):110-122. Pubmedid: 39353825.
• Jazayeri SB, DiNatale RG, Guske C, Harrs C, Linscott J, Xu H, Davaro F, Wen L, Spiess PE, Sexton WJ, Gilbert SM, Zemp L, Poch MA, Li R. Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design. Eur Urol Focus. 2025 Dec. Pubmedid: 41421932.
• Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
• Linscott J, Li R. Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct.212(4):624-625. Pubmedid: 38912644.
• Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Aug.26(8):945-958. Pubmedid: 38837106.
• Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The Elusive Horizon: Biomarkers in Urothelial Carcinoma. Eur Urol. 2024 Apr.85(4):317-319. Pubmedid: 38278663.
• Linscott JA, Sexton WJ. Editorial Comment. J Urol. 2024 Apr.211(4):573-574. Pubmedid: 38241201.
• White RE, Linscott JA, Hayn MT, Ryan ST, Howard JM, James E, Hansen MH, Sammon JD. Distance to Treatment With Radical Cystectomy in a Rural State: Long Car Rides, Equivalent Outcomes. Urol Pract. 2023 Nov.10(6):588-594. Pubmedid: 37647141.
• Hansen NF, Linscott JA, Hayn MH, Ryan ST, Sammon JD. Prostate Specific Antigen Testing Behaviors for Prostate Cancer Screening Among U.S. Immigrants: A Cross-sectional Analysis Using the National Health Interview Survey. J Urol. 2023 Jan.209(1):161-169. Pubmedid: 36250952.
• Pagadala MS, Linscott JA, Talwar JV, Seibert TM, Rose B, Lynch J, Panizzon M, Hauger R, Hansen MH, Sammon JD, Hayn MH, Kader K, Carter H, Ryan ST. PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry. BMC Cancer. 2022 Dec.22(1):1289. Pubmedid: 36494783. Pmcid: PMC9733391.
• Daly WC, Han PKJ, Hayn M, Ryan ST, Hansen MH, Linscott JP, Trinh QD, Sammon JD. Meditative and mind-body practice among patients with genitourinary malignancy. Urol Oncol. 2021 Mar.39(3):192.e15-192.e20. Pubmedid: 33431327.
• Daly WC, Linscott JA, Han PKJ, Hayn MH, Hansen MH, Ryan ST, Remick SC, Sammon JD. National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans. J Urol. 2021 Jun.205(6):1641-1647. Pubmedid: 33530748.
• Linscott JA, Rutan MC, Han PKJ, Hansen MH, Hayn MH, Ryan ST, Trinh QD, Sammon JD. Receipt of Survivorship Care Plans and Self-Reported Health Status among Patients with Genitourinary Malignancy. J Urol. 2020 Sep.204(3):564-569. Pubmedid: 32267200.
• Chen S, Kapilashrami K, Senevirathne C, Wang Z, Wang J, Linscott JA, Luo M. Substrate-Differentiated Transition States of SET7/9-Catalyzed Lysine Methylation. J Am Chem Soc. 2019 May.141(20):8064-8067. Pubmedid: 31034218. Pmcid: PMC6613214.
• Linscott JA, Smith AB, Sammon JD. Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65. Eur Urol. 2018 Apr.73(4):e102-e103. Pubmedid: 29129400.
• Linscott JA, Kapilashrami K, Wang Z, Senevirathne C, Bothwell IR, Blum G, Luo M. Kinetic isotope effects reveal early transition state of protein lysine methyltransferase SET8. Proc Natl Acad Sci U S A. 2016 Dec.113(52):E8369-E8378. Pubmedid: 27940912. Pmcid: PMC5206543.
• Archambault L, Linscott J, Swerdlow N, Boyland K, Riley E, Schlax P. Translational efficiency of rpoS mRNA from Borrelia burgdorferi: effects of the length and sequence of the mRNA leader region. Biochem Bioph Res Co. 2013 Mar.433(1):73-78. Pubmedid: 23454119. Pmcid: PMC3616328.

• Title: Utilizing Cell Free DNA to Detect Minimal Residual Disease and Monitor Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  Award Number:
  Sponsor: American Urological Association (AUA)
  Linscott, J. (PD/PI)